moderna's story is what's the encore to covid-19, says bank of america's geoff meacham
Published 2 years ago • 2.1K plays • Length 3:14Download video MP4
Download video MP3
Similar videos
-
4:34
bank of america senior analyst explains why he's bearish on moderna compared to pfizer
-
3:52
bofa's geoff meacham on pfizer earnings: the story is still about covid contraction
-
4:19
expect eli lilly's momentum to continue, says bank of america's geoff meacham
-
5:28
there are long and short opportunities in tech-focused funds, says citi's mithra warrier
-
2:39
outlook for booster shots not clear: pharma analyst
-
3:17
bofa's geoff meacham on eli lilly on q4 results: the story has changed to diabetes and obesity
-
3:04
why this biotech analyst has a hold rating on moderna
-
3:47
equities are in a 'sweet spot' for the next couple of years, says laffer tengler ceo nancy tengler
-
3:02
moderna ceo: we hope to have covid booster shot ready by the fall
-
50:21
moderna’s co-founder on the sprint for a covid-19 vaccine
-
2:51
clsa strategist says he expects bank of japan to hike rates in december and twice more in 2025
-
2:04
cramer's mad dash: what could move apple higher than nvidia
-
5:02
bofa’s meacham on what's next for eli lilly after fda approves obesity drug
-
4:24
we've only seen the beginning of moderna's story, says goldman sachs' salveen richter
-
4:36
finding more opportunity in securitized credit within private markets, says guggenheim's dilorenzo
-
1:42
moderna forecasts $17-22 billion in sales for 2022
-
3:33
moderna stock hits all time high
-
4:51
andersen: s&p 500 target is 6,600 by year-end.
-
1:48
a snapshot of the global market